secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-06-02T13:02:48+00:00
Accession:  0001129928-26-000039
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oncolytics appoints Steve Glover to board, promotes John McAdory to COO
-----------------------------------------------------------------------

- Steve Glover appointed to board effective June 1, 2026; he chaired Ambrx during its $2B J&J acquisition.
- John McAdory promoted to COO effective June 1, 2026; previously EVP Strategy & Operations since Jan 2026.
- McAdory will oversee clinical ops, preclinical R&D, strategic partnerships, and business development.
- Glover receives an option to purchase 96,000 shares vesting over three years; McAdory receives no extra compensation.
- Glover brings 35+ years biopharma experience; also chairs ZyVersa Therapeutics and sits on PDS Biotech board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000039/0001129928-26-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000039/oncy-20260602.htm
  HTML page:      https://secwatch.observer/filing/0001129928-26-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer